IP
Imbria Pharmaceuticals, Inc.
SEC filingBiotechnology · Boston, MA
Amount raised$66.7Msold at filing
Total offering$144.2M$77.5M still open
Investors in the raise10count reported to the SEC
FiledDec 16, 2025first sale Mar 10, 2025
Form D does not name the investors. If a news report names them, they appear here.
Named in the filing
Pavan CheruvuDirector
Charles DunnDirector
Alvin ShihExecutive Officer, Director
Luse RebeccaDirector
Ken HorneDirector
Komal JoshiExecutive Officer
Andrew LevinDirector
Zina Affas BesseDirector
Executive officers, directors and promoters as listed on the Form D.